Cigna genetic-counseling requirment could hit Myriad

Cigna (CI) will require that patients receive counseling before it will pay for genetic tests for certain cancers and other diseases.

The decision affects checks for the BRCA1 and BRCA2 genes, a leading cause of hereditary breast cancer, and genes for colon cancer and a heart abnormality called long QT syndrome

The requirement could particularly affect Myriad Genetics (MYGN) - 85% of its $613.2M revenue in the last fiscal year came from BRCA tests. Counselors may decide that women need alternative tests not provided by Myriad, or that they don't need to be checked at all.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs